Kalk W J, Durbach D, Kantor S, Levin J
S Afr Med J. 1980 Mar 29;57(13):479-82.
One hundred and fifty-one patients with hyperthyroidism were treated with varying doses of radio-iodine (131I), and the results were analysed 1 year later. Of the patients with Graves' disease who received the lowest 131I doses (mean 2,8 mCi) 39% had persistent thyrotoxicosis and 25% were hypothyroid 12 months after therapy. Moderate doses of 131I (mean 5,9 mCi) reduced the rate of persistent disease to 19% and increased the rate of hypothyroidism by only 4% (P less than 0,05). When 131I dosages were calculated according to thyroid weight (microCi/g), patients who received the lowest doses (mean 115 microCi/g) again had significant rates of both persistent hyperthyroidism (38%) and hypothyroidism (24%). These data indicate that very low doses of 131I in the treatment of Graves's disease may result in a high incidence of persistent disease, but do not necessarily result in a very low incidence of early hypothyroidism. Low-dose 131I regimens are unsuitable for treatment of thyrotoxicosis unless very good facilities for patient follow-up are available.
151例甲状腺功能亢进患者接受了不同剂量的放射性碘（131I）治疗，并于1年后分析结果。在接受最低剂量131I（平均2.8毫居里）的格雷夫斯病患者中，39%在治疗12个月后仍有持续性甲状腺毒症，25%出现甲状腺功能减退。中等剂量的131I（平均5.9毫居里）可将持续性疾病的发生率降至19%，并仅使甲状腺功能减退的发生率增加4%（P<0.05）。当根据甲状腺重量计算131I剂量（微居里/克）时，接受最低剂量（平均115微居里/克）的患者再次出现较高的持续性甲状腺功能亢进（38%）和甲状腺功能减退（24%）发生率。这些数据表明，极低剂量的131I治疗格雷夫斯病可能导致持续性疾病的高发生率，但不一定导致早期甲状腺功能减退的低发生率。低剂量131I治疗方案不适合治疗甲状腺毒症，除非有非常完善的患者随访设施。
